GlobalData on MSN14h
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key clinical candidates for these companies: ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback